Drug Shortages Back In US Congressional Spotlight
Drug shortages were a significant focus of legislative attention in the US before the COVID-19 pandemic, and Congress is not likely to drop the issue now that the public health emergency is winding down.
You may also be interested in...
President Biden’s 100-day plan relies on Defense Production Act authorities to increase resilience of critical domestic pharmaceutical supplies.
US FDA excludes chronic care products from list of medicines bolstered by domestic production investment and federal procurement requirements.
If the US FDA could track production, it could anticipate shortages – and national security threats from countries like China.